Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
2007 Annual Meeting of the Canadian Anesthesiologists’ Society
Hemostatic Therapy Advances in Trauma and Surgery
Calgary, Alberta / June 22-26, 2007
Calgary - Major bleeding substantially increases patient risk in any clinical situation, regardless of whether it is the primary problem as in hemophilia or secondary to surgery or traumatic injury. Options for controlling bleeding remain...
33rd Annual Meeting of the European Group for Blood and Marrow Transplantation
Targeted Therapy in Lymphoid Malignancies: The Changing Face of Transplantation
Lyon, France / March 25-28, 2007
Lyon - Treatment of non-Hodgkin’s lymphoma generally involves chemotherapy. Autologous or allogeneic stem cell transplantation is often considered in patients who are refractory to chemotherapy. Despite intensive research in previous...
33rd Annual Meeting of the European Group for Blood and Marrow Transplantation
Update on Antifungal Treatment Strategies in Stem Cell Transplantation
Lyon, France / March 25-28, 2007
Invasive aspergillosis is a major problem in the management of patients who have undergone stem cell transplantation (SCT). According to figures presented by Prof. Noel Milpied, University Hospital, Bordeaux, France, the incidence of these...
12th Annual Update on Cardiopulmonary Bypass
Transfusion Medicine in Cardiac Surgery: Towards Implementation of a Blood Conservation Program
Whistler, British Columbia / March 18-23, 2007
Whistler - There is an urgent need to minimize the use of all blood products in cardiac surgery, speakers here agreed, not only because blood is increasingly scarce and costly, but because transfusion itself is also associated with...
48th Annual Meeting and Exposition of the American Society of Hematology
Chronic Lymphocytic Leukemia: Novel Algorithms in Early Disease
Orlando, Florida / December 9-12, 2006
Orlando - New data suggest that both treatments and treatment goals are evolving in chronic lymphocytic leukemia (CLL). While recent studies have associated new strategies with incremental improvements in anti-CLL activity, particularly a...
48th Annual Meeting and Exposition of the American Society of Hematology
Low Molecular-weight Heparins for High-risk Patients in Context of Clot Mechanisms
Orlando, Florida / December 9-12, 2006
Orlando - The multiple mechanisms that promote venous thromboembolism (VTE) in patients with acute illnesses or cancer has been the basis for considering broader indications for prophylaxis. In a new meta-analysis of studies, low...
48th Annual Meeting and Exposition of the American Society of Hematology
Improved Outcomes with Immunochemotherapy in Indolent and Related Lymphomas
Orlando, Florida / December 9-12, 2006
Orlando - A comparison of two consecutive studies in advanced follicular lymphoma showed that response rates, time to treatment failure and overall survival were significantly improved with...
48th Annual Meeting and Exposition of the American Society of Hematology
New Hope for Patients with Advanced, Resistant Cutaneous T-cell Lymphomas and Chronic Myeloid Leukemia
Orlando, Florida / December 9-12, 2006
Orlando - Cutaneous T-cell lymphomas (CTCLs) are rare tumours but when they become advanced, treatment options are limited. A novel treatment class, the histone deacetylase inhibitors, which includes vorinostat, have produced meaningful...
48th Annual Meeting and Exposition of the American Society of Hematology
Novel Agents Offer New Promise in Relapsed, Refractory Multiple Myeloma and Newly Diagnosed Disease
Orlando, Florida / December 9-12, 2006
Orlando - Novel agents that target pathways other than those affected by traditional chemotherapy agents are emerging as promising new options in second-line relapsed/refractory multiple myeloma (MM) as well as induction agents or as...